From a clinical point of view, it is noteworthy that, while COX-2 in tumour cells identifies cervical cancer patients with unfavourable prognosis, COX-2 expression in stroma inflammatory compartment is associated with better clinical outcome, suggesting that COX-2 positive stromal cells can play a role in reducing tumour cell aggressiveness. This evidence concerns the gene PTGS2 and cervical cancer.